Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported an open-market sale of 18,586 shares of common stock at $38.06 per share. After this transaction on June 11, 2026, he directly holds 227,923 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026, indicating it was scheduled in advance rather than timed discretionarily.

Insights

Insider trading and governance analyst

CSO makes pre-planned share sale while retaining a substantial remaining stake.

Chief Scientific Officer Christian Heidbreder sold 18,586 shares of Indivior Pharmaceuticals, Inc. common stock at $38.06 per share in an open-market transaction. Following the sale, he continues to hold 227,923 shares directly, which keeps him significantly exposed to the company’s equity.

The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026. Such plans are established in advance and aim to reduce concerns that trades are based on undisclosed information, so the timing of this sale carries limited informational value about short-term prospects.

There are no derivative positions reported in this filing, and the data show only this single sale transaction. Future company filings may provide additional context on ongoing compensation, equity holdings, or further transactions by senior executives.

Insider Trade Summary 10b5-1

Net Seller: 18,586 shares ($707,383)

Net Sell 1 txn

Insider Heidbreder Christian

Role Chief Scientific Officer

Sold 18,586 shs ($707K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,586	$38.06	$707K

Holdings After Transaction: Common Stock — 227,923 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 18,586 shares Sale price: $38.06 per share Shares held after sale: 227,923 shares +2 more

5 metrics

Shares sold 18,586 shares Open-market sale on June 11, 2026

Sale price $38.06 per share Common Stock transaction

Shares held after sale 227,923 shares Direct ownership following transaction

Trading plan adoption date March 13, 2026 Rule 10b5-1 trading plan used for sale

Transaction code S Sale in open market or private transaction

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heidbreder Christian

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VIRGINIA 23235

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		S(1)		18,586	D	$38.06	227,923	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

Remarks:

	/s/Alice Givens, Power of Attorney	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Indivior (INDV) report for Christian Heidbreder?

Indivior reported that Chief Scientific Officer Christian Heidbreder sold 18,586 shares of common stock. The sale was an open-market transaction at $38.06 per share, and it was executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in 2026.

How many Indivior (INDV) shares does Christian Heidbreder hold after this Form 4 sale?

After the reported sale, Chief Scientific Officer Christian Heidbreder directly holds 227,923 shares of Indivior common stock. This figure comes from the Form 4 disclosure of total shares following the transaction dated June 11, 2026, and reflects his remaining direct ownership position.

At what price were the Indivior (INDV) shares sold in the latest Form 4?

The Form 4 shows that 18,586 Indivior common shares were sold at an average price of $38.06 per share. The transaction is coded as an open-market or private sale and represents a planned disposition under a Rule 10b5-1 trading arrangement.

Was the Indivior (INDV) insider sale by Christian Heidbreder under a Rule 10b5-1 plan?

Yes. A footnote states the sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This indicates the trade was scheduled in advance rather than decided at the last moment.

What role does Christian Heidbreder hold at Indivior (INDV) in this Form 4?

In this Form 4, Christian Heidbreder is identified as an officer of Indivior Pharmaceuticals, Inc., serving as Chief Scientific Officer. The filing classifies his ownership as direct for the reported common stock sale and subsequent holdings.